;PMID: 11088049
;source_file_574.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..167] = [t:40..167]
;2)section:[e:171..238] = [t:171..238]
;3)section:[e:242..321] = [t:242..321]
;4)sentence:[e:325..351] = [t:325..351]
;5)sentence:[e:352..495] = [t:352..495]
;6)sentence:[e:496..612] = [t:496..612]
;7)sentence:[e:613..809] = [t:613..809]
;8)sentence:[e:810..818] = [t:810..818]
;9)sentence:[e:819..916] = [t:819..916]
;10)sentence:[e:917..1076] = [t:917..1076]
;11)sentence:[e:1077..1085] = [t:1077..1085]
;12)sentence:[e:1086..1166] = [t:1086..1166]
;13)sentence:[e:1167..1226] = [t:1167..1226]
;14)sentence:[e:1227..1326] = [t:1227..1326]
;15)sentence:[e:1327..1408] = [t:1327..1408]
;16)sentence:[e:1409..1457] = [t:1409..1457]
;17)sentence:[e:1458..1549] = [t:1458..1549]
;18)sentence:[e:1550..1609] = [t:1550..1609]
;19)sentence:[e:1610..1764] = [t:1610..1764]
;20)sentence:[e:1765..1865] = [t:1765..1865]
;21)sentence:[e:1866..1975] = [t:1866..1975]
;22)sentence:[e:1976..1988] = [t:1976..1988]
;23)sentence:[e:1989..2101] = [t:1989..2101]
;24)sentence:[e:2102..2218] = [t:2102..2218]
;25)section:[e:2219..2250] = [t:2219..2250]
;26)section:[e:2254..2299] = [t:2254..2299]

;section 0 Span:0..35
;J Surg Oncol  2000 Nov;75(3):176-85
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Surg) (NNP:[7..12] Oncol) (CD:[14..18] 2000)
        ('':[19..25] Nov;75) (-LRB-:[25..26] -LRB-) (CD:[26..27] 3)
        (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..31] 17) (::[31..35] 6-85)))

;sentence 1 Span:40..167
;Comparison of K-ras point mutations at codon 12 and p21 expression in
;pancreatic  cancer between Japanese and Chinese patients.
;[54..59]:gene-rna:"K-ras"
;[60..75]:variation-type:"point mutations"
;[79..87]:variation-location:"codon 12"
;[92..95]:gene-protein:"p21"
;[110..128]:malignancy:"pancreatic  cancer"
(SENT
  (NP-HLN
    (NP (NN:[40..50] Comparison))
    (PP (IN:[51..53] of)
      (NP
        (NP
          (NP (NN:[54..59] K-ras)
             (NN:[60..65] point) (NNS:[66..75] mutations))
          (PP-LOC (IN:[76..78] at)
            (NP (NN:[79..84] codon) (CD:[85..87] 12))))
        (CC:[88..91] and)
        (NP (NN:[92..95] p21) (NN:[96..106] expression))))
    (PP (IN:[107..109] in)
      (NP (JJ:[110..120] pancreatic) (NN:[122..128] cancer)))
    (PP (IN:[129..136] between)
      (NP
        (NP (JJ:[137..145] Japanese)
          (NML-1 (-NONE-:[145..145] *P*)))
        (CC:[146..149] and)
        (NP (JJ:[150..157] Chinese)
          (NML-1 (NNS:[158..166] patients)))))
    (.:[166..167] .)))

;section 2 Span:171..238
;Song MM, Nio Y, Dong M, Tamura K, Furuse K, Tian YL, He SG, Shen K.
(SEC
  (FRAG (NNP:[171..175] Song) (NNP:[176..178] MM) (,:[178..179] ,)
        (NNP:[180..183] Nio) (NNP:[184..185] Y) (,:[185..186] ,)
        (NNP:[187..191] Dong) (NNP:[192..194] M,) (NNP:[195..201] Tamura)
        (NNP:[202..204] K,) (NNP:[205..211] Furuse) (NNP:[212..214] K,)
        (NNP:[215..219] Tian) (NNP:[220..222] YL) (,:[222..223] ,)
        (NNP:[224..226] He) (NNP:[227..229] SG) (,:[229..230] ,)
        (NNP:[231..235] Shen) (NNP:[236..238] K.)))

;section 3 Span:242..321
;First Department of Surgery, Shimane Medical University, Izumo, Shimane,
;Japan.
(SEC
  (FRAG (NNP:[242..247] First) (NNP:[248..258] Department) (IN:[259..261] of)
        (NNP:[262..269] Surgery) (,:[269..270] ,) (NNP:[271..278] Shimane)
        (NNP:[279..286] Medical) (NNP:[287..297] University) (,:[297..298] ,)
        (NNP:[299..304] Izumo) (,:[304..305] ,) (NNP:[306..313] Shimane)
        (,:[313..314] ,) (NNP:[315..320] Japan) (.:[320..321] .)))

;sentence 4 Span:325..351
;BACKGROUND ANF OBJECTIVES:
(SENT
  (NP (NN:[325..335] BACKGROUND) (CC:[336..339] ANF) (NNS:[340..350] OBJECTIVES)
      (::[350..351] :)))

;sentence 5 Span:352..495
;K-ras (Kirsten-ras) point mutation (PM) in codon 12  are suggested to be
;significantly associated with the tumorigenesis of  pancreatic cancer.
;[352..357]:gene-rna:"K-ras"
;[359..370]:gene-rna:"Kirsten-ras"
;[372..386]:variation-type:"point mutation"
;[388..390]:variation-type:"PM"
;[395..403]:variation-location:"codon 12"
;[477..494]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NML
          (NML (NN:[352..357] K-ras))
          (NML (-LRB-:[358..359] -LRB-) (NN:[359..370] Kirsten-ras)
               (-RRB-:[370..371] -RRB-)))
        (NML
          (NML (NN:[372..377] point) (NN:[378..386] mutation))
          (NML (-LRB-:[387..388] -LRB-) (NN:[388..390] PM)
               (-RRB-:[390..391] -RRB-))))
      (PP-LOC (IN:[392..394] in)
        (NP (NN:[395..400] codon) (CD:[401..403] 12))))
    (VP (VBP:[405..408] are)
      (VP (VBN:[409..418] suggested)
        (S
          (NP-SBJ-1 (-NONE-:[418..418] *))
          (VP (TO:[419..421] to)
            (VP (VB:[422..424] be)
              (ADVP (RB:[425..438] significantly))
              (VP (JJ:[439..449] associated)
                (NP-1 (-NONE-:[449..449] *))
                (PP-CLR (IN:[450..454] with)
                  (NP
                    (NP (DT:[455..458] the) (NN:[459..472] tumorigenesis))
                    (PP (IN:[473..475] of)
                      (NP (JJ:[477..487] pancreatic) (NN:[488..494] cancer)))))))))))
    (.:[494..495] .)))

;sentence 6 Span:496..612
;The incidences of K-ras PMs in human pancreatic cancer are  reported to be
;different between Europeans and Japanese.
;[514..519]:gene-rna:"K-ras"
;[520..523]:variation-type:"PMs"
;[533..550]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[496..499] The) (NNS:[500..510] incidences))
      (PP (IN:[511..513] of)
        (NP (NN:[514..519] K-ras) (NNS:[520..523] PMs)))
      (PP (IN:[524..526] in)
        (NP (JJ:[527..532] human)
           (JJ:[533..543] pancreatic) (NN:[544..550] cancer))))
    (VP (VBP:[551..554] are)
      (VP (VBN:[556..564] reported)
        (S
          (NP-SBJ-1 (-NONE-:[564..564] *))
          (VP (TO:[565..567] to)
            (VP (VB:[568..570] be)
              (ADJP-PRD (JJ:[571..580] different)
                (PP (IN:[581..588] between)
                  (NP (NNPS:[589..598] Europeans) (CC:[599..602] and)
                      (NNPS:[603..611] Japanese)))))))))
    (.:[611..612] .)))

;sentence 7 Span:613..809
;The present study was  designed to compare the incidences and profile of
;K-ras PMs and ras-p21  expression in primary invasive ductal carcinoma (IDC)
;of the pancreas between  Japanese and Chinese.
;[686..691]:gene-rna:"K-ras"
;[692..695]:variation-type:"PMs"
;[700..707]:gene-protein:"ras-p21"
;[723..778]:malignancy:"primary invasive ductal carcinoma (IDC) of the
;pancreas"
;[758..761]:malignancy:"IDC"
(SENT
  (S
    (NP-SBJ-1 (DT:[613..616] The) (JJ:[617..624] present) (NN:[625..630] study))
    (VP (VBD:[631..634] was)
      (VP (VBN:[636..644] designed)
        (NP-1 (-NONE-:[644..644] *))
        (S-PRP
          (NP-SBJ (-NONE-:[644..644] *))
          (VP (TO:[645..647] to)
            (VP (VB:[648..655] compare)
              (NP
                (NP (DT:[656..659] the) (NNS:[660..670] incidences)
                    (CC:[671..674] and) (NN:[675..682] profile))
                (PP (IN:[683..685] of)
                  (NP
                    (NP (NN:[686..691] K-ras) (NNS:[692..695] PMs))
                    (CC:[696..699] and)
                    (NP
                      (NML (NN:[700..703] ras) (HYPH:[703..704] -)
                           (NN:[704..707] p21))
                      (NN:[709..719] expression))))
                (PP (IN:[720..722] in)
                  (NP
                    (NP (JJ:[723..730] primary)
                      (NML
                        (NML (JJ:[731..739] invasive) (JJ:[740..746] ductal)
                             (NN:[747..756] carcinoma))
                        (NML (-LRB-:[757..758] -LRB-) (NN:[758..761] IDC)
                             (-RRB-:[761..762] -RRB-))))
                    (PP (IN:[763..765] of)
                      (NP (DT:[766..769] the) (NN:[770..778] pancreas))))))
              (PP (IN:[779..786] between)
                (NP (NNPS:[788..796] Japanese) (CC:[797..800] and)
                    (NNPS:[801..808] Chinese))))))))
    (.:[808..809] .)))

;sentence 8 Span:810..818
;METHODS:
(SENT
  (NP (NNS:[810..817] METHODS) (::[817..818] :)))

;sentence 9 Span:819..916
;The specimens included 51 Japanese and 34 Chinese  patients with the primary
;IDC of the pancreas.
;[888..915]:malignancy:"primary IDC of the pancreas"
(SENT
  (S
    (NP-SBJ (DT:[819..822] The) (NNS:[823..832] specimens))
    (VP (VBD:[833..841] included)
      (NP
        (NP
          (NP (CD:[842..844] 51) (JJ:[845..853] Japanese)
            (NML-1 (-NONE-:[853..853] *P*)))
          (CC:[854..857] and)
          (NP (CD:[858..860] 34) (JJ:[861..868] Chinese)
            (NML-1 (NNS:[870..878] patients))))
        (PP (IN:[879..883] with)
          (NP
            (NP (DT:[884..887] the) (JJ:[888..895] primary) (NN:[896..899] IDC))
            (PP (IN:[900..902] of)
              (NP (DT:[903..906] the) (NN:[907..915] pancreas)))))))
    (.:[915..916] .)))

;sentence 10 Span:917..1076
;K-ras PMs were tested by allele  specific oligonucleotide dot blot
;hybridization methods and ras-p21 expression  was stained by the
;immunohistochemical method.
;[917..922]:gene-rna:"K-ras"
;[923..926]:variation-type:"PMs"
;[1010..1017]:gene-protein:"ras-p21"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[917..922] K-ras) (NNS:[923..926] PMs))
      (VP (VBD:[927..931] were)
        (VP (VBN:[932..938] tested)
          (NP-2 (-NONE-:[938..938] *))
          (PP-MNR (IN:[939..941] by)
            (NP
              (ADJP (NN:[942..948] allele) (JJ:[950..958] specific))
              (NN:[959..974] oligonucleotide)
              (NML (NN:[975..978] dot) (NN:[979..983] blot))
              (NN:[984..997] hybridization) (NNS:[998..1005] methods))))))
    (CC:[1006..1009] and)
    (S
      (NP-SBJ-1
        (NML (NN:[1010..1013] ras) (HYPH:[1013..1014] -) (NN:[1014..1017] p21))
        (NN:[1018..1028] expression))
      (VP (VBD:[1030..1033] was)
        (VP (VBN:[1034..1041] stained)
          (NP-1 (-NONE-:[1041..1041] *))
          (PP-MNR (IN:[1042..1044] by)
            (NP (DT:[1045..1048] the) (JJ:[1049..1068] immunohistochemical)
                (NN:[1069..1075] method))))))
    (.:[1075..1076] .)))

;sentence 11 Span:1077..1085
;RESULTS:
(SENT
  (NP (NNS:[1077..1084] RESULTS) (::[1084..1085] :)))

;sentence 12 Span:1086..1166
;K-ras PMs were detected  in 48 Japanese IDCs (94%) and in 24 Chinese ones
;(71%).
;[1086..1091]:gene-rna:"K-ras"
;[1092..1095]:variation-type:"PMs"
;[1126..1130]:malignancy:"IDCs"
(SENT
  (S
    (NP-SBJ-1 (NN:[1086..1091] K-ras) (NNS:[1092..1095] PMs))
    (VP (VBD:[1096..1100] were)
      (VP (VBN:[1101..1109] detected)
        (NP-1 (-NONE-:[1109..1109] *))
        (PP-LOC
          (PP (IN:[1111..1113] in)
            (NP (CD:[1114..1116] 48) (JJ:[1117..1125] Japanese)
                (NNS:[1126..1130] IDCs)
              (PRN (-LRB-:[1131..1132] -LRB-)
                (NP (CD:[1132..1134] 94) (NN:[1134..1135] %))
                (-RRB-:[1135..1136] -RRB-))))
          (CC:[1137..1140] and)
          (PP (IN:[1141..1143] in)
            (NP (CD:[1144..1146] 24) (JJ:[1147..1154] Chinese)
                (NNS:[1155..1159] ones)
              (PRN (-LRB-:[1160..1161] -LRB-)
                (NP (CD:[1161..1163] 71) (NN:[1163..1164] %))
                (-RRB-:[1164..1165] -RRB-)))))))
    (.:[1165..1166] .)))

;sentence 13 Span:1167..1226
;There was a significant  difference between the two groups.
(SENT
  (S
    (NP-SBJ (EX:[1167..1172] There))
    (VP (VBD:[1173..1176] was)
      (NP-PRD
        (NP (DT:[1177..1178] a) (JJ:[1179..1190] significant)
            (NN:[1192..1202] difference))
        (PP (IN:[1203..1210] between)
          (NP (DT:[1211..1214] the) (CD:[1215..1218] two)
              (NNS:[1219..1225] groups)))))
    (.:[1225..1226] .)))

;sentence 14 Span:1227..1326
;The GAT mutation was more frequent both in  Japanese (61%, 33/54) and in
;Chinese (60%, 18/30) IDCs.
;[1231..1234]:variation-state-generic:"GAT"
;[1235..1243]:variation-event:"mutation"
;[1321..1325]:malignancy:"IDCs"
(SENT
  (S
    (NP-SBJ (DT:[1227..1230] The) (NN:[1231..1234] GAT)
            (NN:[1235..1243] mutation))
    (VP (VBD:[1244..1247] was)
      (ADJP-TMP-PRD (RBR:[1248..1252] more) (JJ:[1253..1261] frequent))
      (PP-LOC (CC:[1262..1266] both)
        (PP (IN:[1267..1269] in)
          (NP (JJ:[1271..1279] Japanese)
            (PRN (-LRB-:[1280..1281] -LRB-)
              (FRAG
                (NP (CD:[1281..1283] 61) (NN:[1283..1284] %))
                (,:[1284..1285] ,)
                (NP
                  (NP (CD:[1286..1288] 33))
                  (PP (SYM:[1288..1289] /)
                    (NP (CD:[1289..1291] 54)))))
              (-RRB-:[1291..1292] -RRB-))
            (NML-1 (-NONE-:[1292..1292] *P*))))
        (CC:[1293..1296] and)
        (PP (IN:[1297..1299] in)
          (NP (JJ:[1300..1307] Chinese)
            (PRN (-LRB-:[1308..1309] -LRB-)
              (FRAG
                (NP (CD:[1309..1311] 60) (NN:[1311..1312] %))
                (,:[1312..1313] ,)
                (NP
                  (NP (CD:[1314..1316] 18))
                  (PP (SYM:[1316..1317] /)
                    (NP (CD:[1317..1319] 30)))))
              (-RRB-:[1319..1320] -RRB-))
            (NML-1 (NNS:[1321..1325] IDCs))))))
    (.:[1325..1326] .)))

;sentence 15 Span:1327..1408
;The  transitions/transversions ratio in the Japanese group was 2.4 in this
;study.
;[1332..1343]:variation-type:"transitions"
;[1344..1357]:variation-type:"transversions"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1327..1330] The)
        (NML (NNS:[1332..1343] transitions) (SYM:[1343..1344] /)
             (NNS:[1344..1357] transversions))
        (NN:[1358..1363] ratio))
      (PP (IN:[1364..1366] in)
        (NP (DT:[1367..1370] the) (JJ:[1371..1379] Japanese)
            (NN:[1380..1385] group))))
    (VP (VBD:[1386..1389] was)
      (NP-PRD (CD:[1390..1393] 2.4))
      (PP (IN:[1394..1396] in)
        (NP (DT:[1397..1401] this) (NN:[1402..1407] study))))
    (.:[1407..1408] .)))

;sentence 16 Span:1409..1457
;By  contrast, that in the Chinese group was 1.5.
(SENT
  (S
    (PP (IN:[1409..1411] By)
      (NP (NN:[1413..1421] contrast)))
    (,:[1421..1422] ,)
    (NP-SBJ
      (NP (DT:[1423..1427] that))
      (PP (IN:[1428..1430] in)
        (NP (DT:[1431..1434] the) (JJ:[1435..1442] Chinese)
            (NN:[1443..1448] group))))
    (VP (VBD:[1449..1452] was)
      (NP-PRD (CD:[1453..1456] 1.5)))
    (.:[1456..1457] .)))

;sentence 17 Span:1458..1549
;The expression of p21 was detected  in 24 Japanese IDCs (47%) and in 24
;Chinese IDCs (71%).
;[1476..1479]:gene-protein:"p21"
;[1509..1513]:malignancy:"IDCs"
;[1538..1542]:malignancy:"IDCs"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1458..1461] The) (NN:[1462..1472] expression))
      (PP (IN:[1473..1475] of)
        (NP (NN:[1476..1479] p21))))
    (VP (VBD:[1480..1483] was)
      (VP (VBN:[1484..1492] detected)
        (NP-1 (-NONE-:[1492..1492] *))
        (PP-LOC
          (PP (IN:[1494..1496] in)
            (NP (CD:[1497..1499] 24) (JJ:[1500..1508] Japanese)
                (NNS:[1509..1513] IDCs)
              (NP (-LRB-:[1514..1515] -LRB-)
                (NP (CD:[1515..1517] 47) (NN:[1517..1518] %))
                (-RRB-:[1518..1519] -RRB-))))
          (CC:[1520..1523] and)
          (PP (IN:[1524..1526] in)
            (NP (CD:[1527..1529] 24) (JJ:[1530..1537] Chinese)
                (NNS:[1538..1542] IDCs)
              (PRN (-LRB-:[1543..1544] -LRB-)
                (NP (CD:[1544..1546] 71) (NN:[1546..1547] %))
                (-RRB-:[1547..1548] -RRB-)))))))
    (.:[1548..1549] .)))

;sentence 18 Span:1550..1609
;There was a significant  difference between the two groups.
(SENT
  (S
    (NP-SBJ (EX:[1550..1555] There))
    (VP (VBD:[1556..1559] was)
      (NP-PRD
        (NP (DT:[1560..1561] a) (JJ:[1562..1573] significant)
            (NN:[1575..1585] difference))
        (PP (IN:[1586..1593] between)
          (NP (DT:[1594..1597] the) (CD:[1598..1601] two)
              (NNS:[1602..1608] groups)))))
    (.:[1608..1609] .)))

;sentence 19 Span:1610..1764
;The expression of p21 and the patterns of  K-ras PMs did not show any
;significant influence on the survival of the patients  both in Japanese and
;Chinese.
;[1628..1631]:gene-protein:"p21"
;[1653..1658]:gene-rna:"K-ras"
;[1659..1662]:variation-type:"PMs"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1610..1613] The) (NN:[1614..1624] expression))
        (PP (IN:[1625..1627] of)
          (NP (NN:[1628..1631] p21))))
      (CC:[1632..1635] and)
      (NP
        (NP (DT:[1636..1639] the) (NNS:[1640..1648] patterns))
        (PP (IN:[1649..1651] of)
          (NP (NN:[1653..1658] K-ras) (NNS:[1659..1662] PMs)))))
    (VP (VBD:[1663..1666] did) (RB:[1667..1670] not)
      (VP (VB:[1671..1675] show)
        (NP
          (NP (DT:[1676..1679] any) (JJ:[1680..1691] significant)
              (NN:[1692..1701] influence))
          (PP (IN:[1702..1704] on)
            (NP
              (NP (DT:[1705..1708] the) (NN:[1709..1717] survival))
              (PP (IN:[1718..1720] of)
                (NP (DT:[1721..1724] the) (NNS:[1725..1733] patients))))))
        (PP (CC:[1735..1739] both) (IN:[1740..1742] in)
          (NP (NNPS:[1743..1751] Japanese) (CC:[1752..1755] and)
              (NNPS:[1756..1763] Chinese)))))
    (.:[1763..1764] .)))

;sentence 20 Span:1765..1865
;In the present study, Chinese IDC had a lower  frequency of K-ras PMs in
;codon 12 than Japanese IDC.
;[1795..1798]:malignancy:"IDC"
;[1825..1830]:gene-rna:"K-ras"
;[1831..1834]:variation-type:"PMs"
;[1838..1846]:variation-location:"codon 12"
;[1861..1864]:malignancy:"IDC"
(SENT
  (S
    (PP (IN:[1765..1767] In)
      (NP (DT:[1768..1771] the) (JJ:[1772..1779] present)
          (NN:[1780..1785] study)))
    (,:[1785..1786] ,)
    (NP-SBJ (JJ:[1787..1794] Chinese) (NN:[1795..1798] IDC))
    (VP (VBD:[1799..1802] had)
      (NP
        (NP (DT:[1803..1804] a) (JJR:[1805..1810] lower)
            (NN:[1812..1821] frequency))
        (PP (IN:[1822..1824] of)
          (NP
            (NP (NN:[1825..1830] K-ras) (NNS:[1831..1834] PMs))
            (PP-LOC (IN:[1835..1837] in)
              (NP (NN:[1838..1843] codon) (CD:[1844..1846] 12)))))
        (PP (IN:[1847..1851] than)
          (NP (JJ:[1852..1860] Japanese) (NN:[1861..1864] IDC)))))
    (.:[1864..1865] .)))

;sentence 21 Span:1866..1975
;The pattern of K-ras PMs  in Chinese IDC was different from that in Japanese
;and European IDC,  respectively.
;[1881..1886]:gene-rna:"K-ras"
;[1887..1890]:variation-type:"PMs"
;[1903..1906]:malignancy:"IDC"
;[1956..1959]:malignancy:"IDC"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1866..1869] The) (NN:[1870..1877] pattern))
      (PP (IN:[1878..1880] of)
        (NP (NN:[1881..1886] K-ras) (NNS:[1887..1890] PMs)))
      (PP (IN:[1892..1894] in)
        (NP (JJ:[1895..1902] Chinese) (NN:[1903..1906] IDC))))
    (VP (VBD:[1907..1910] was)
      (ADJP-PRD
        (ADJP (JJ:[1911..1920] different))
        (PP (IN:[1921..1925] from)
          (NP
            (NP (DT:[1926..1930] that))
            (PP (IN:[1931..1933] in)
              (NP
                (NP (JJ:[1934..1942] Japanese)
                  (NML-1 (-NONE-:[1942..1942] *P*)))
                (CC:[1943..1946] and)
                (NP (JJ:[1947..1955] European)
                  (NML-1 (NN:[1956..1959] IDC))))))))
      (,:[1959..1960] ,)
      (ADVP (RB:[1962..1974] respectively)))
    (.:[1974..1975] .)))

;sentence 22 Span:1976..1988
;CONCLUSIONS:
(SENT
  (NP (NNS:[1976..1987] CONCLUSIONS) (::[1987..1988] :)))

;sentence 23 Span:1989..2101
;Ki-ras PM and p21 expression were frequently seen  both in Japanese and
;Chinese patients with pancreatic cancer.
;[1989..1995]:gene-rna:"Ki-ras"
;[1996..1998]:variation-type:"PM"
;[2003..2006]:gene-protein:"p21"
;[2083..2100]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1989..1995] Ki-ras) (NN:[1996..1998] PM))
      (CC:[1999..2002] and)
      (NP (NN:[2003..2006] p21) (NN:[2007..2017] expression)))
    (VP (VBD:[2018..2022] were)
      (ADVP (RB:[2023..2033] frequently))
      (VP (VBN:[2034..2038] seen)
        (NP-2 (-NONE-:[2038..2038] *))
        (PP-LOC (CC:[2040..2044] both) (IN:[2045..2047] in)
          (NP
            (NP
              (NP (JJ:[2048..2056] Japanese)
                (NML-1 (-NONE-:[2056..2056] *P*)))
              (CC:[2057..2060] and)
              (NP (JJ:[2061..2068] Chinese)
                (NML-1 (NNS:[2069..2077] patients))))
            (PP (IN:[2078..2082] with)
              (NP (JJ:[2083..2093] pancreatic) (NN:[2094..2100] cancer)))))))
    (.:[2100..2101] .)))

;sentence 24 Span:2102..2218
;Factors such as  lifestyle and environment may have influences on pancreatic
;carcinogenesis in  various populations.
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[2102..2109] Factors))
      (PP (JJ:[2110..2114] such) (IN:[2115..2117] as)
        (NP (NN:[2119..2128] lifestyle) (CC:[2129..2132] and)
            (NN:[2133..2144] environment))))
    (VP (MD:[2145..2148] may)
      (VP (VB:[2149..2153] have)
        (NP (NNS:[2154..2164] influences)
          (PP (IN:[2165..2167] on)
            (NP (JJ:[2168..2178] pancreatic) (NN:[2179..2193] carcinogenesis)))
          (PP (IN:[2194..2196] in)
            (NP (JJ:[2198..2205] various) (NNS:[2206..2217] populations))))))
    (.:[2217..2218] .)))

;section 25 Span:2219..2250
;Copyright 2000 Wiley-Liss, Inc.
(SEC
  (FRAG (NN:[2219..2228] Copyright) (CD:[2229..2233] 2000)
        (NNP:[2234..2239] Wiley) (HYPH:[2239..2240] -) (NNP:[2240..2244] Liss)
        (,:[2244..2245] ,) (NNP:[2246..2250] Inc.)))

;section 26 Span:2254..2299
;PMID: 11088049 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2254..2258] PMID) (::[2258..2259] :) (CD:[2260..2268] 11088049)
        (NN:[2269..2270] -LSB-) (NNP:[2270..2276] PubMed) (::[2277..2278] -)
        (NN:[2279..2286] indexed) (IN:[2287..2290] for)
        (NNP:[2291..2299] MEDLINE-RSB-)))
